FORT COLLINS — St. Renatus LLC, a Fort Collins-based biopharmaceutical company, has received FDA approval for its first product, a dental anesthetic.
Kovanaze allows dental anesthesia to be administered through a nasal spray without using a needle. It is designed for use in procedures involving most of the upper teeth.
“For more than 100 years, the dental industry has delivered dental anesthesia using a needle injection. Now, through the efforts of a dedicated team, we have developed a revolutionary needle-free method for delivering pulpal anesthesia,” said Steve Merrick, St. Renatus’ chief executive.
Kovanaze is intended for use in dentistry as a topical anesthetic, delivered in the nasal cavity to achieve pulpal, or tooth nerve, anesthesia.
St. Renatus was formed in 2008 and has raised approximately $40 million in funding to pursue the development and approval of the nasal mist.